Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Article Pathology

Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas

Paul A. Christensen et al.

Summary: The Omicron variant of SARS-CoV-2 has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases. A study found that patients infected with Omicron were younger, had higher vaccine breakthrough rates, and were less likely to be hospitalized compared to patients with other variants. They also required less respiratory support and had shorter hospital stays, indicating reduced disease severity.

AMERICAN JOURNAL OF PATHOLOGY (2022)

Add to Collection

Article Hematology

COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA

Livio Pagano et al.

BLOOD (2022)

Add to Collection

Article Hematology

COVID-19 in patients with hematologic malignancy

Petra Langerbeins et al.

BLOOD (2022)

Add to Collection

Editorial Material Hematology

Is COVID vaccine effective in patients with myeloid malignancy?

Moshe Mittelman

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Review Oncology

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

Simone Cesaro et al.

Summary: SARS-CoV-2 infection can lead to severe outcomes in immunocompromised hematological patients, with high mortality rates observed. Treatment strategies focus on controlling viral replication and inflammation. However, the effectiveness and benefits of preventive and therapeutic measures in hematological patients require further investigation.

LEUKEMIA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years

Ronen Arbel et al.

Summary: A retrospective analysis of data from Israel shows that a second booster shot of BNT162b2 in individuals aged 60 and over significantly reduces hospitalizations and deaths due to COVID-19.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

Yinon M. Bar-On et al.

Summary: After administering the fourth dose of BNT162b2 vaccine to individuals aged 60 years and older during the period when the omicron variant was predominant, Israel observed lower rates of confirmed SARS-CoV-2 infection and severe Covid-19 compared to those who received only three doses. The protection against severe illness remained consistent, while the protection against confirmed infection decreased over time.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Oncology

Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review

Vanessa Piechotta et al.

Summary: The efficacy of COVID-19 vaccination in patients with hematological malignancies appears limited and varies across different diseases and treatments. Clinical outcomes are rarely reported, with low rates of infection, symptomatic disease, hospital admission, and death. Seroconversion rates show heterogeneity, with lower response rates in patients receiving B-cell depleting treatment. Vaccine-induced T-cell response and adverse events are rarely reported as well.

BLOOD CANCER JOURNAL (2022)

Add to Collection

Letter Hematology

Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report

Ola Blennow et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Oncology

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Livio Pagano et al.

Summary: This study analyzed baseline characteristics and predictors of mortality in hematological malignancy patients with COVID-19. Results showed that a high percentage of patients developed severe/critical symptoms, with a mortality rate of 31.2%, although improved prevention measures have decreased mortality rates despite an increase in reported cases.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report

Related references

Export Citation

Share Paper